Phase II 'up-front window study' of irinotecan (CPT-11) followed by multimodal, multiagent, therapy for selected children and adolescents with newly diagnosed stage 4/clinical group IV rhabdomyosarcoma: An IRS-V study
Phase of Trial: Phase II
Latest Information Update: 13 Feb 2014
At a glance
- Drugs Irinotecan (Primary) ; Cyclophosphamide; Dactinomycin; Vincristine
- Indications Rhabdomyosarcoma; Sarcoma
- Focus Therapeutic Use
- 24 Sep 2005 New trial record.